rs121918350
Variant summary
Our verdict is Pathogenic. Variant got 19 ACMG points: 19P and 0B. PM1PM2PM5PP2PP3_StrongPP5_Very_Strong
The NM_000214.3(JAG1):c.550C>T(p.Arg184Cys) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.000000684 in 1,461,892 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. 13/21 in silico tools predict a damaging outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. R184G) has been classified as Likely pathogenic.
Frequency
Consequence
NM_000214.3 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 19 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
JAG1 | NM_000214.3 | c.550C>T | p.Arg184Cys | missense_variant | 4/26 | ENST00000254958.10 | NP_000205.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
JAG1 | ENST00000254958.10 | c.550C>T | p.Arg184Cys | missense_variant | 4/26 | 1 | NM_000214.3 | ENSP00000254958.4 | ||
JAG1 | ENST00000423891.6 | n.416C>T | non_coding_transcript_exon_variant | 2/25 | 2 |
Frequencies
GnomAD3 genomes Cov.: 33
GnomAD4 exome AF: 6.84e-7 AC: 1AN: 1461892Hom.: 0 Cov.: 34 AF XY: 0.00000138 AC XY: 1AN XY: 727248
GnomAD4 genome Cov.: 33
ClinVar
Submissions by phenotype
Alagille syndrome due to a JAG1 point mutation Pathogenic:3
Pathogenic, no assertion criteria provided | literature only | OMIM | Jun 01, 1998 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Neuberg Centre For Genomic Medicine, NCGM | - | The missense variant c.550C>T (p.Arg184Cys) in JAG1 gene has been reported in affected individuals in the literature (Crosnier C et.al.,2001). This variant has been reported to the ClinVar database as Pathogenic. The p.Arg184Cys variant is novel (not in any individuals) in gnomAD Exomes and 1000 Genomes. The amino acid Arg at position 184 is changed to a Cys changing protein sequence and it might alter its composition and physico-chemical properties. The variant is predicted to be damaging by both SIFT and PolyPhen2. The residue is conserved across species. The amino acid change p.Arg184Cys in JAG1 is predicted as conserved by GERP++ and PhyloP across 100 vertebrates. For these reasons, this variant has been classified as Pathogenic . - |
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Oct 23, 2023 | This sequence change replaces arginine, which is basic and polar, with cysteine, which is neutral and slightly polar, at codon 184 of the JAG1 protein (p.Arg184Cys). This variant is not present in population databases (gnomAD no frequency). This missense change has been observed in individual(s) with Alagille syndrome (PMID: 9585603, 22405927). In at least one individual the variant was observed to be de novo. ClinVar contains an entry for this variant (Variation ID: 7619). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) has been performed at Invitae for this missense variant, however the output from this modeling did not meet the statistical confidence thresholds required to predict the impact of this variant on JAG1 protein function. This variant disrupts the p.Arg184 amino acid residue in JAG1. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 10220506, 10533065, 22487239, 24748328). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic. - |
not provided Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Eurofins Ntd Llc (ga) | Oct 17, 2017 | - - |
JAG1-related disorder Pathogenic:1
Pathogenic, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | Jul 08, 2024 | The JAG1 c.550C>T variant is predicted to result in the amino acid substitution p.Arg184Cys. This variant has been reported with de novo occurrence in at least two patients with Alagille syndrome (see example: Table 2, Krantz et al. 1998. PubMed ID: 9585603; Table 2, Li et al. 2015. PubMed ID: 26076142). To our knowledge, this variant has not been reported in a large population database, indicating it is rare. In addition, different variants affecting the same amino acid (Arg184Gly, Arg184His) have also been reported to be pathogenic for Alagille syndrome (Krantz et al. 1998. PubMed ID: 9585603; Crosnier et al. 1999. PubMed ID: 10220506). This variant is interpreted as pathogenic. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at